14 Phase II trial evaluating efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Peritoneal Cancer ◽

Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial

Gynecologic Oncology ◽

10.1016/j.ygyno.2021.08.005 ◽

2021 ◽

Author(s):

Mathew Cowan ◽

Wendy M. Swetzig ◽

Valery Adorno-Cruz ◽

Mario J. Pineda ◽

Nikki L. Neubauer ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Efficacy And Safety ◽

Peritoneal Cancer ◽

Phase II trial of weekly nab-paclitaxel with GM-CSF as an immune modulator in recurrent platinum resistant ovarian, fallopian tube, and primary peritoneal cancer: Clinical and immune responses.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.5580 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 5580-5580

Author(s):

John Ben Liao ◽

Ron E. Swensen ◽

Jessica Reichow ◽

Kelsie J Ovenell ◽

Jennifer Childs ◽

...

Keyword(s):

Immune Responses ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Peritoneal Cancer ◽

Immune Modulator ◽

Gm Csf ◽

Randomized phase II trial of weekly ixabepilone with or without biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00753-8 ◽

2021 ◽

Vol 162 ◽

pp. S58

Author(s):

Dana Roque ◽

Eric Siegel ◽

Natalia Buza ◽

Stefania Bellone ◽

Dan-Arin Silasi ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Randomized Phase Ii

A multicentre phase II study of AZD1775 plus chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Annals of Oncology ◽

10.1093/annonc/mdx372.061 ◽

2017 ◽

Vol 28 ◽

pp. v352-v353

Author(s):

K.N. Moore ◽

K.A. Cadoo ◽

S. Chambers ◽

S. Ghamande ◽

G. Konecny ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Multicentre Phase ◽

Peritoneal Cancer ◽

5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71174-6 ◽

2007 ◽

Vol 5 (4) ◽

pp. 311-312

Author(s):

S. Makhija ◽

D. Glenn ◽

F. Ueland ◽

D. Dizon ◽

V. Paton ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Double Blind Trial ◽

Double Blind ◽

Peritoneal Cancer ◽

Blind Trial ◽

Efficacy and safety of standard of care with/without bevacizumab for platinum‐resistant ovarian/fallopian tube/peritoneal cancer previously treated with bevacizumab: the Japanese Gynecologic Oncology Group study JGOG3023

Cancer Science ◽

10.1111/cas.15185 ◽

2021 ◽

Author(s):

Tadahiro Shoji ◽

Takayuki Enomoto ◽

Masakazu Abe ◽

Aikou Okamoto ◽

Takayuki Nagasawa ◽

...

Keyword(s):

Fallopian Tube ◽

Gynecologic Oncology ◽

Standard Of Care ◽

Gynecologic Oncology Group ◽

Efficacy And Safety ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Platinum Resistant ◽

Previously Treated

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.979 ◽

2020 ◽

Vol 31 ◽

pp. S630

Author(s):

L. Xia ◽

Q. Zhou ◽

Y. Zhang ◽

Y. Gao ◽

W. Hu ◽

...

Keyword(s):

Cervical Cancer ◽

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Study ◽

Advanced Cervical Cancer ◽

Open Label ◽

Peritoneal Cancer ◽

Multicenter Phase ◽

A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study

Gynecologic Oncology ◽

10.1016/j.ygyno.2018.10.001 ◽

2018 ◽

Vol 151 (3) ◽

pp. 422-427 ◽

Cited By ~ 7

Author(s):

Bradley J. Monk ◽

James T. Kauderer ◽

Katherine M. Moxley ◽

Albert J. Bonebrake ◽

Summer B. Dewdney ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Weekly Paclitaxel ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽

Phase II trial of pemetrexed and carboplatin in platinum-sensitive recurrent ovarian, fallopian tube, and primary peritoneal cancer

Gynecologic Oncology ◽

10.1016/j.ygyno.2014.03.120 ◽

2014 ◽

Vol 133 ◽

pp. 41

Author(s):

A. Van Arsdale ◽

M.H. Einstein ◽

M.A. Brewer ◽

P.F. Timmins ◽

J.D. Wright ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Phase Ii Trial ◽

Peritoneal Cancer ◽

Platinum Sensitive

A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: A Gynecologic Oncology Group Study

Gynecologic Oncology ◽

10.1016/j.ygyno.2011.03.036 ◽

2011 ◽

Vol 122 (1) ◽

pp. 111-115 ◽

Cited By ~ 57

Author(s):

Robert L. Coleman ◽

William E. Brady ◽

D. Scott McMeekin ◽

Peter G. Rose ◽

John T. Soper ◽

...

Keyword(s):

Fallopian Tube ◽

Phase Ii ◽

Gynecologic Oncology ◽

Gynecologic Oncology Group ◽

Oncology Group ◽

Oncology Group Study ◽

Peritoneal Cancer ◽